Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
<strong>Background<br></strong> The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impa...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2022
|
| _version_ | 1797107405102776320 |
|---|---|
| author | Li Bassi, G Gibbons, K Suen, JY Dalton, HJ White, N Corley, A Shrapnel, S Hinton, S Forsyth, S Laffey, JG Fan, E Fanning, JP Panigada, M Bartlett, R Brodie, D Burrell, A Chiumello, D Elhazmi, A Esperatti, M Grasselli, G Hodgson, C Ichiba, S Luna, C Marwali, E Merson, L Murthy, S Nichol, A Ogino, M Pelosi, P Torres, A Ng, PY Fraser, JF |
| author2 | COVID-19 Critical Care Consortium |
| author_facet | COVID-19 Critical Care Consortium Li Bassi, G Gibbons, K Suen, JY Dalton, HJ White, N Corley, A Shrapnel, S Hinton, S Forsyth, S Laffey, JG Fan, E Fanning, JP Panigada, M Bartlett, R Brodie, D Burrell, A Chiumello, D Elhazmi, A Esperatti, M Grasselli, G Hodgson, C Ichiba, S Luna, C Marwali, E Merson, L Murthy, S Nichol, A Ogino, M Pelosi, P Torres, A Ng, PY Fraser, JF |
| author_sort | Li Bassi, G |
| collection | OXFORD |
| description | <strong>Background<br></strong>
The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis.
<br><strong>
Methods<br></strong>
We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression.
<br><strong>
Results<br></strong>
Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0–25) and 25 (IQR 7–26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0–87) and 87 (IQR 0–88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.177).
<br><strong>
Conclusions<br></strong>
In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting. |
| first_indexed | 2024-03-07T07:14:06Z |
| format | Journal article |
| id | oxford-uuid:99efeedd-1ef4-4d7a-88c0-91ed7cb6f6ba |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:14:06Z |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:99efeedd-1ef4-4d7a-88c0-91ed7cb6f6ba2022-07-27T19:58:05ZEarly short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:99efeedd-1ef4-4d7a-88c0-91ed7cb6f6baEnglishSymplectic ElementsBioMed Central2022Li Bassi, GGibbons, KSuen, JYDalton, HJWhite, NCorley, AShrapnel, SHinton, SForsyth, SLaffey, JGFan, EFanning, JPPanigada, MBartlett, RBrodie, DBurrell, AChiumello, DElhazmi, AEsperatti, MGrasselli, GHodgson, CIchiba, SLuna, CMarwali, EMerson, LMurthy, SNichol, AOgino, MPelosi, PTorres, ANg, PYFraser, JFCOVID-19 Critical Care Consortium<strong>Background<br></strong> The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis. <br><strong> Methods<br></strong> We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression. <br><strong> Results<br></strong> Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0–25) and 25 (IQR 7–26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0–87) and 87 (IQR 0–88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.177). <br><strong> Conclusions<br></strong> In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting. |
| spellingShingle | Li Bassi, G Gibbons, K Suen, JY Dalton, HJ White, N Corley, A Shrapnel, S Hinton, S Forsyth, S Laffey, JG Fan, E Fanning, JP Panigada, M Bartlett, R Brodie, D Burrell, A Chiumello, D Elhazmi, A Esperatti, M Grasselli, G Hodgson, C Ichiba, S Luna, C Marwali, E Merson, L Murthy, S Nichol, A Ogino, M Pelosi, P Torres, A Ng, PY Fraser, JF Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis |
| title | Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis |
| title_full | Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis |
| title_fullStr | Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis |
| title_full_unstemmed | Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis |
| title_short | Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis |
| title_sort | early short course of neuromuscular blocking agents in patients with covid 19 ards a propensity score analysis |
| work_keys_str_mv | AT libassig earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT gibbonsk earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT suenjy earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT daltonhj earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT whiten earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT corleya earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT shrapnels earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT hintons earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT forsyths earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT laffeyjg earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT fane earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT fanningjp earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT panigadam earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT bartlettr earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT brodied earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT burrella earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT chiumellod earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT elhazmia earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT esperattim earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT grassellig earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT hodgsonc earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT ichibas earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT lunac earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT marwalie earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT mersonl earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT murthys earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT nichola earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT oginom earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT pelosip earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT torresa earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT ngpy earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis AT fraserjf earlyshortcourseofneuromuscularblockingagentsinpatientswithcovid19ardsapropensityscoreanalysis |